First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations ( ESR1 m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS2) from the phase III SERENA-6 trial.

Journal of Clinical Oncology 2026

View at publisher
Authors: Francois Clement Bidard, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni, Cynthia X. Ma, Massimo Cristofanilli, Giampaolo Bianchini, Kevin Kalinsky, Hiroji Iwata, Stephen K.L. Chia, Adam Brufsky, Peter A. Fasching
+8 more Zbigniew Nowecki, Javier Pascual, N. Karadurmus, Einav Nili Gal‐Yam, Arkendu Chatterjee, Manuel Selvi Miralles, Cynthia Huang Bartlett, Nicholas C. Turner
DOI: 10.1200/jco.2026.44.17_suppl.lba1007
Cited by: 2

Abstract

LBA1007 Background: CAMI is a next-generation SERD and complete ER antagonist. SERENA-6 enrolled patients (pts) with HR+/HER2− ABC receiving 1L aromatase inhibitor (AI) + CDK4/6i and without disease progression. Switching to CAMI, with continued CDK4/6i, at ESR1 m emergence during 1L AI + CDK4/6i significantly improved PFS (HR: 0.44 [95% CI: 0.31–0.60]; p

Fields of Study & Subjects

Advanced Breast Cancer Therapies Estrogen and related hormone effects Breast Cancer Treatment Studies

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
17_suppl
Publication date
3 June 2026
Language
EN